中文名称 | (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-二羟基-3-((R)-1-((1S,3R,4R)-4-(2-羟基乙氧基)-3-甲氧基环己基)丙-2-基)-10,21-二甲氧基-6,8,12,14,20,26-六甲基-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-十六氢-3H-23,27-环氧吡啶并[21-c][1]氧杂]4]氮杂环;依维莫司 |
---|---|
英文名称 | Everolimus | RAD-001 |
CAS号 | 159351-69-6 |
分子式 | C53H83NO14 |
分子量 | 958.22 |
MDL | MFCD00929329 |
外观 | White to off-white powder |
储存条件 | Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years). |
Everolimus, also known as RAD001, is a derivative of the natural macrocyclic lactone sirolimus with immunosuppressant and anti-angiogenic properties. In cells, everolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. Inhibition of mTOR activation results in the inhibition of T lymphocyte activation and proliferation associated with antigen and cytokine (IL-2, IL-4, and IL-15) stimulation and the inhibition of antibody production.
© 2020-2024 凯立德生物医药技术(上海)有限公司 版权所有
沪ICP备15046197号-3
沪公网安备31011502007856号
Designed by Kuanersoft